Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
Frequently asked questions
What sector does TRML (TRML) operate in?
TRML belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TRML (TRML) current stock price?
As of the latest data, TRML stock price is $47.98, with a previous close of $47.98.
What is TRML (TRML) current market capitalization?
TRML market cap is approximately 1.23 billion.
What is TRML (TRML) Earnings Per Share (EPS)?
The trailing EPS is -$3.44, and the forward EPS is -$4.25.
Does TRML (TRML) pay dividends?
No. TRML does not pay a dividend.
What is TRML (TRML) beta (volatility) score?
TRML has a beta of 1.581, suggesting it is more volatile than the market.